Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
February 12, 2025
To, The Listing Department National Stock Exchange Of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: VIJAYA
To, The Corporate Relations Department BSE Limited, Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 543350
Dear Sir/Madam,
Sub: Investor Presentation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on Financial Results for quarter and nine months ended December 31, 2024, which would be used in the Investors / Analysts earnings conference call scheduled to be held on February 12, 2025, at 05:30 p.m. (IST).
Please take the information on record.
Thanking you, For Vijaya Diagnostic Centre Limited
Hansraj Singh Company Secretary & Compliance Officer M. No. F11438
Encl.: As Above
Q3 & 9M FY25 Earnings Presentation
February 12, 2025
Q2 & H1 FY25 Earnings Presentation, November 07, 2024
Safe Harbour
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
2
Disclaimer
Note 1:
Disclaimer
Acquisition (PH Diagnostic Centre Private Limited, Pune) : PH has become a whole owned subsidiary effective from 21st December 2023. Consequently, its financials have been consolidated from 21st December 2023 in the last financial year FY 2023-24.
Hence, the consolidated operational and financial figures of Q2 FY25, Q3 FY25, Q3 FY24, 9M FY25 and 9M FY24 in the subsequent slides are including PH, unless otherwise stated.
3
Strategic Expansion
Q3 & 9M FY25 Performance Snapshot
Q3 FY25 Performance Snapshot
Financial Performance
Key Metrics
INR 1,690 Mn Revenue from Operations
INR 1,580 Mn Revenue excluding PH
INR 671 Mn | 39.7% EBITDA | EBITDA Margin %
INR 352 Mn | 20.8% PAT | PAT Margin %
1.05 Mn
Footfall
149
Centres
3.68 Mn
Tests
93%
B2C Revenue %
YOY Growth %
Geographical Contribution
Wellness Share%
27.3%
27.6%
19.3%
Revenue Growth %
Test Volume Growth %
Footfall Growth %
20.2%
20.0%
15.0%
Revenue Growth (1) %
Test Volume Growth (1) %
Footfall Growth (1) %
3%
6%
1%
14.1%
18%
72%
Hyderabad
RoAPT
Pune
Kolkata
Others
Welness Share %
1. Organic growth excluding PH
5
9M FY25 Performance Snapshot
Financial Performance
Key Metrics
INR 5,081 Mn Revenue from Operations
INR 4,736 Mn Revenue excluding PH
INR 2,044 Mn | 40.2%
INR 1,084 Mn | 21.3%
EBITDA | EBITDA Margin %
PAT | PAT Margin %
3.14 Mn
Footfall
149
Centres
11.00 Mn
Tests
93%
B2C Revenue %
YOY Growth % (1)
Geographical Contribution
Wellness Share%
29.4%
29.0%
22.1%
Revenue Growth %
Test Volume Growth %
Footfall Growth %
21.0%
20.7%
16.6%
Revenue Growth (1) %
Test Volume Growth (1) %
Footfall Growth (1) %
3%
1%
7%
17%
72%
13.7%
Hyderabad
RoAPT
Pune
Kolkata
Others
Welness Share %
1. Organic growth excluding PH
6
Management Commentary
“
I’m pleased to announce another strong quarter, marked by a remarkable year-on-year
revenue growth of 27.3%, with a solid 20.2% growth achieved organically. This strong
performance was primarily driven by volume across both Pathology and Radiology segments.
I am happy to share that we have operationalized our 1st centre at Pimple Saudagar, Pune
(Spoke) under Vijaya PH Brand in this month, following the PH acquisition.
Looking ahead, I am excited to announce that we would be commissioning 6 hubs across
Pune, West Bengal and Bengaluru in the coming 3 months, taking our total hub addition to 9
in the 12-month period which marks a significant milestone in the history of Vijaya.
We have also made key strategic hires at the mid and senior levels across functions to support
” the management in driving the next phase of growth.
7
Commenting on the performance for Q3 FY25, Ms. Suprita Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said:
Key Financial Highlights – Q3 & 9M FY25
Revenue from Operations (INR Mn)
EBITDA & EBITDA Margin %
PAT & PAT Margin %
Key
Financials
1,327
1,829
1,690
39.4%
41.5%
39.7%
40.2%
40.2%
19.5%
22.9%
20.8%
21.7%
21.3%
5,081
3,926
2,044
1,578
523
760
671
259
419
352
1,084
854
Q3 FY24 Q2 FY25 Q3 FY25
9M FY24
9M FY25
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
Radiology vs. Pathology Breakdown %
B2C Revenue %
Wellness share %
Radiology
Pathology
Revenue
Mix
64%
65%
63%
64%
63%
94%
93%
93%
95%
93%
12.2%
13.7%
14.1%
12.5%
13.7%
36%
35%
37%
36%
37%
Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
8
Key Operational Highlights
Tests Performed (# in Mn)
Footfalls (# in Mn)
Tests / Footfalls (# in Mn)
11.00
8.53
2.88
3.95
3.68
0.88
1.13
1.05
3.14
2.57
3.49
3.52
3.50
3.29
3.32
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
Revenue per Test (INR)
Revenue per Footfall (INR)
461
463
460
460
462
1,515
1,526
1,616
1,616
1,618
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
Q3 FY24
Q2 FY25
Q3 FY25
9M FY24
9M FY25
9
Consolidated Profit & Loss Statement
Particulars
Q3 FY25
Q3 FY24
Y-o-Y
Q2 FY25
Q-o-Q
9M FY25
9M FY24
Y-o-Y
Revenue from operations
1,689.8
1,326.9
Cost of materials consumed
Employee benefits expense
Other expenses
EBITDA
EBITDA Margin (%)
Other income
Depreciation and amortization expense
EBIT
Finance costs
Profit before Exceptional Items & Tax
Exceptional Items
Profit before Tax
Tax expenses
Profit before Minority Interest
Minority Interest
Profit after Tax (PAT)
PAT Margin (%)
EPS – Basic (INR)*
208.5
285.5
524.4
671.3
159.9
230.3
413.7
523.1
39.7%
39.4%
47.0
183.0
535.2
68.2
467.0
-
467.0
114.1
353.0
1.4
351.6
20.8%
3.4
51.1
145.4
428.7
60.6
368.1
20.5
347.6
87.6
260.0
1.5
258.5
19.5%
2.5
27.3%
30.4%
24.0%
26.8%
28.3%
31BPS
-8.1%
25.9%
24.8%
12.5%
26.9%
-100.0%
34.3%
30.2%
35.8%
-6.5%
36.0%
132BPS
35.3%
1,829.5
229.9
278.4
561.4
759.8
41.5%
45.1
168.4
636.6
64.7
571.9
-
571.9
150.6
421.2
1.9
419.4
22.9%
4.1
-7.6%
-9.3%
2.6%
-6.6%
-11.6%
-181BPS
4.1%
8.7%
-15.9%
5.4%
-18.3%
-18.3%
-24.3%
-16.2%
-24.3%
-16.2%
-212BPS
-16.3%
5,081.5
3,926.0
626.0
837.5
1,574.5
2,043.5
40.2%
127.7
517.8
1,653.5
195.5
1,457.9
-
1,457.9
368.6
1,089.3
4.9
1,084.4
21.3%
10.6
466.2
657.0
1,224.9
1,577.9
40.2%
175.7
407.0
1,346.6
178.0
1,168.6
20.5
1,148.1
288.5
859.6
5.9
853.7
21.7%
8.4
29.4%
34.3%
27.5%
28.5%
29.5%
2BPS
-27.3%
27.2%
22.8%
9.9%
24.8%
-100.0%
27.0%
27.8%
26.7%
-16.1%
27.0%
-41BPS
26.6%
(INR Mn)
*Not annualized
10
Key Developments
Strategic Expansion
1
Strengthening Leadership Team for the Next Leg of Growth
Sivaramaraju Vegesna
Elevated from Head – Strategy & Investor Relations
VP - Operations
VP - Sales
Praveen Velmury
GM - Strategy
Vishal Gurram
AGM – Strategy & Investor Relations
Dhiren Gala
Total Experience: 3 Decades+
Total Experience: 12+ years
Total Experience: 6+ years
Last Experience: Business Head for all
Last Experience: Business Head at
Last Experience: Investment Banker at
verticals of Havells across AP, TS & Karnataka
Quadrangle
Investec Capital
PGDDM from IIM Calcutta
MBA from IIM Lucknow
B.Tech. from NIT Warangal
MBA from SPJIMR
Chartered Accountant
12
2
Inaugurated a state-of-the-art Hub in Nizamabad, Telangana
Inaugurated State-of-the-Art Hub in Nizamabad in Nov, 2024 in line with our focus on expansion in key geographies within Tier II & Tier III cities
Nizamabad
9,000+ sq.ft. Hub houses advanced equipment like 3T MRI and CT Scan
New Benchmark set with “All Under One Roof Model” in Nizamabad District
13
3
Inaugurated a Spoke in Bhuvanagiri, Telangana
Inaugurated a Spoke in Bhuvanagiri in Nov, 2024 in line with our strategy of deepening presence in our core markets
Bhuvanagiri
1,500+ sq.ft. Spoke houses machinery for X-Ray, ECG and all kinds of Blood Tests
The spoke enhances our Telangana market footprint
14
4
Introduced PET-CT Machine in Tirupati Centre, AP
PET-CT machine has been successfully introduced at Tirupati Centre, AP in Nov, 2024
Tirupati
Strategic introduction based on significant cancer infra investments by Govt and Private sector in the city
City hosts established medical centers, Oncology focused hospitals & a growing number of oncology specialists
15
5
Received No-Objection Letter from Stock Exchanges
Received No-objection letter from stock exchanges for the merger between Vijaya Diagnostics and Medinova Diagnostic Services in December, 2024
The NCLT process has commenced and is expected to conclude in 4-5 months
16
Strategic Expansion
Strategic Expansion
Expanding Strategically in Alignment with our Vision
Inorganic Expansion Strategy
• Successfully acquired PH, Pune's largest B2C
integrated diagnostic chain
• This strategic acquisition seamlessly aligns
with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values
• Operationalized our 1st Spoke centre at
Pimple Saudagar under Vijaya PH Brand in February, 2025, following the acquisition
• We aspire to consolidate our presence gradually by building a denser network
Expansion into Neighbouring State
•
Identified Bangalore as a key Tier 1 market and plan to enter through organic route
East India Strategy
•
•
Inaugurated our second hub and the first under the Vijaya brand in North Kolkata
Employing our proven hub and spoke model, we aim to replicate our success in East India by creating a dense network
Core Market Strategy
• Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles,
strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed
• During FY25, we have opened a hub center in Ongole, AP, in August, 2024 and Nizamabad,
Telangana in November, 2024 along with 2 spokes as part of our strategy to deepen presence in our core geography
18
Expansion Plans - Upcoming Hubs and Spokes Centres
Geography
Count & Type
Tentative Timelines for Commencement
Next 3 months
Pune
West Bengal
Bengaluru
RoAPT
Hyderabad
1. Leases for 2 more hubs in RoAPT are under finalisation
2 Hubs
2 Spokes
5 Hubs
Next 3 months
Next 3 months
2 Hubs in next 3 months
3 Hubs in next 3-6 months
2 Hubs
Next 3 months
2 Hubs (1)
H2 FY26
2 Spokes
Next 3-6 months
6 Hubs
2 Spokes
Next 3 - 6 months
3 Hubs
2 Spokes
Total Next 6 months
9 Hubs
4 Spokes
19
Company Overview
Strategic Expansion
Vijaya at a Glance
Vijaya Diagnostic Centre is the largest integrated diagnostic chain in South India with 149 state-of-the-art centres spread across 25 cities & towns
Evolved from a regional player to a player with presence in multiple geographies …
… While retaining its core values of providing Quality, Reliable & Accurate Diagnostic Services at Affordable Prices
149 Centres
40+ Years of Vintage
17 labs with NABL Accreditation
Founded by Mr. Surendranath Reddy in 1981 and currently led by Mrs. Suprita Reddy
25 Cities and towns across India
300+ Doctors
Largest integrated player in South India
Radiologists, Pathologists & Microbiologists network
~4.12 Mn Footfalls (1)
Trusted by every Age group
~14.36 Mn Tests (2)
Most preferred Diagnostic Centre
21
1. Footfall and Tests for the 12 months ended 31-Dec-24
Our Journey
1981
1993
1995 2007
2003
2012
2005 2016
▪ Vijaya Diagnostic Centre
incorporated in Hyderabad
▪ Became 1st Independent diagnostic centre in South India to offer PET CT from Wipro GE Healthcare
▪ Recognized as one of the Best Imaging centres in Hyderabad by The Week
▪ Received investment from
Karakoram Limited & Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF1
2020
2006
2008
2019
2010
2013 2018
▪ One of the earliest private
diagnostic service providers to be approved for COVID RT- PCR testing by ICMR*
▪ Awarded Best Diagnostic Centre – India by Times Healthcare Achievers Group
▪ Awarded Brand of the year in diagnostic services by The CEO Magazine and Telangana Healthcare Leadership award
2021
2022
2023
2024
▪ Successfully listed on Indian Stock
Exchanges (NSE* & BSE*)
▪ 1st independent diagnostic centre in Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare
▪ Awarded one of the Best Healthcare Brands 2022 by The Economic Times
▪ Won the Healthcare Leadership
Awards 2022
▪ Awarded Pride of India Brands Award – The Best of South Awards 2022
▪ Successfully launched the first center in Kolkata under the "Vijaya“ brand name
▪ Acquired 100% stake in P.H. Diagnostics and forayed into Pune
▪ Awarded Best Brand at ET Edge
Awards 2023
▪ Transitioned to AI Power Pack –
“Augmento”
▪ Awarded Icon in Integrated Diagnostic Services by Times Health Excellence
▪ Recognized as Fastest Growing
Brands at Asian business & Social Forum 2024, Dubai
* ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange
22
Integrated Diagnostics Player Offering One-Stop Solution
Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience
Complete Range of Diagnostic Services under One Roof
Pathology (1)
63%
Radiology (1)
37%
1. Revenue mix for Q3 FY25
23
Dominant Position in Telangana & AP Markets with a Strong Brand Recall …
Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets
Present in Key Geographies of AP & Telangana
72 (1) %
Hyderabad Revenue Contribution
Mancherial
Nizamabad
Karimnagar
Hanamkonda
Hyderabad & Secunderabad
Vishakhapatnam
Mahabubnagar
Rajahmundry
Kurnool
Nandyal
Ongole
Nellore
Tirupati
18 (1) %
RoAPT Revenue Contribution
A dense network created across AP & Telangana aids in distributing patient load and offering significantly faster TAT across tests
24
1. For the period Q3 FY25
… and Driving Geographical Diversification through Strategic Expansion
Hyderabad
Pune
RoAPT
Gurgaon
Kalaburagi
West Bengal
72%
73%
78%
83%
Geographical Revenue Mix
18%
18%
17% 14%
6%
7%
2%
0%
4%
3%
3%
2%
Q3 FY25
Q2 FY25 FY24 FY23
Q3 FY25
Q2 FY25 FY24 FY23
Q3 FY25
Q2 FY25 FY24 FY23
Q3 FY25
Q2 FY25 FY24 FY23
Vijaya is well-placed to attract customers in new geographies due to its integrated offering and strong emphasis on customer experience
25
RoAPT - Rest of AP and Telangana
Boosting Accessibility with Best-in-class Online Services & Home Collections
Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings
Elevating Customer Experience through Home Collections
Online Services
Home Collections
Access to reports online & historical medical records
Intuitive(1) & user-friendly interface
Agile customer service team
High Brand salience
High customer stickiness
Organic word of mouth growth
1. Patient can track his / her health trends over time
2. Post Collection
Seamless & Efficient process
Temperature Controlled Logistics
High standards of hygiene maintained
Pre-sealed & sterilized single-use home kit
Reaches Lab within 2 hours (2)
26
Robust Technical Capabilities with State-of-the-art IT Infrastructure
33
9
Advanced Software to Manage Clinical Data
CT Machines
PET CT / Gamma machines
33
MRI Machines
10
300+
Radiologists, Lab Doctors & Physicians
17
NABH Accreditations
NABL Accreditations
Key Suppliers
• Long standing relationship with medical technology vendors
• At the forefront of introducing new tests by adopting the latest medical
technologies
• Among the first diagnostic service provider in South India to offer PET-CT scan
in 2008
Advance Laboratory Information Management System (LIMS)
Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)
Front end IT infrastructure enabling…
Standardization across our operations
Reduce errors due Human Intervention
incidence of Low to
Monitor Operations
Technical
Closely track key performance metrics and maintain the Turn- Around Time (TAT)
Provide Uniform Experience to booking from customers appointments accessing to reports online
Vijaya has been ahead of the curve in getting best-in-class & latest diagnostic equipments in India which has helped in offering high quality services
27
Transitioned to AI Power Pack Radiology Software in Q3 FY25
Digitised Images
Digitised Reports
High Quality Reports
Faster TAT
▪ Digitised Radiology images can be shared with the customers as well as clinicians on whatsapp and text, eliminating the need for physical x-ray copies
▪ Radiology test reports can be
accessed online by the customers vs physical reports shared earlier due to integration between Augmento & the billing software
▪ Since the work list is centralised, it can be accessed 24*7 anywhere
▪ Report will be of highest
quality due to specialised doctor reporting the case
▪ Helps enhance customer
experience due to faster TAT and high quality reports
▪ Faster TAT with real-time patient records and cases assigned on FIFO basis to concerned specialists
Sourced from a reputed vendor whose software has been adopted by leading Singapore Public Hospitals
Incorporating the AI Power Pack has streamlined process flow, enhanced customer experience & improved operational efficiency across radiology tests
28
Experienced Board of Directors
Dr. S. Surendranath Reddy Founder & Exec. Chairman
✔ 40+ years of experience ✔ Holds Bachelor’s degree in Medicine and Doctor of Medicine in Radiology
Ms. Suprita Reddy Managing Director & Chief Executive Officer
✔ 22+ years of experience ✔ Awarded Women Leadership Award in Healthcare by ABP
Mr. Sunil Chandra Kondapally Executive Director
S Geeta Reddy Non-Executive Director
✔ 22+ years of experience ✔ Holds Bachelor’s degree in Electrical Engineering from Florida State University
✔ 35+ years of experience ✔ BOD at Sura Agritech, Iffco
Kisan, Namrata Diagnostics, etc.
✔ LLB from Osmania University
Dr. D Nageshwar Reddy Non-Executive Independent Director
✔ Chairman of AIG (1), Hyderabad ✔ Received Padma Shri & Padma Bhushan from Govt of India ✔ D.M (2) from PGIMER Chandigarh
Mr. Shekhar Prasad Singh Non-Executive Independent Director
✔ 40+ years of experience ✔ Ex-Chief Secretary to
Government of Telangana ✔ Retired IAS officer of 1983 batch
Mr. S. Murthy Chavali Non-Executive Independent Director
Dr. Manjula Anagani Non-Executive Independent Director
✔ 35+ years of experience ✔ Ex-CEO - Aurigene Discovery Tech ✔ MBA from IIM, Bangalore & BTech
from IIT, Madras
✔ 25+ years of experience ✔ Clinical Director & HOD - Centre of women & childcare - Care hospitals
✔ Awarded Padma Shri by GOI
1. Asian Institute of Gastroenterology
2. In Gastroenterology
29
Stellar Management Team
Dr. S. Surendranath Reddy Founder & Exec. Chairman
✔ 40+ years of experience ✔ Holds Bachelor’s degree in Medicine and Doctor of Medicine in Radiology
Ms. Suprita Reddy Managing Director & Chief Executive Officer
✔ 22+ years of experience ✔ Awarded Women
Leadership Award in Healthcare by ABP
Mr. Sunil Chandra Kondapally Executive Director
✔ 22+ years of experience ✔ Holds Bachelor’s degree in Electrical Engineering from Florida State University
Mr. Narasimha Raju K.A Chief Financial Officer
✔ 18+ years of experience ✔ Ex-EY, NSL Renewable
Power
✔ Chartered Accountant (CA)
Mr. Sivaramaraju Vegesna, CFA VP Operations
✔ 12+ years of experience ✔ Ex-KIMS Hospitals, NSL Sugars ✔ CFA Charter Holder, MBA from Amity University
Mr. Praveen Velmury VP Sales
✔ 30+ years of experience ✔ Ex-Havells, Vodafone, Nestle ✔ PGDDM from IIM Calcutta
Mr. Hansraj Singh Rajput Company Secretary & Compliance Officer
✔ 10+ years of experience ✔ Ex-Zen Technologies, Gati ✔ LLB & PGDM from NALSAR
Mr. Vishal Gurram GM - Strategy
Mr. Dhiren Gala AGM – Investor Relations
✔ 12+ years of experience ✔ Ex-Medplus, LetsTransport ✔ MBA from IIM Lucknow &
BTech from NIT Warangal
✔ 6+ years of experience ✔ Ex-Investec, Axis Capital ✔ MBA from SPJIMR & CA
30
Shareholding Pattern as at 31st December, 2024
Shareholding Pattern as at 31st December, 2024
Others 4.0%
FIIs 17.5%
DIIs 24.6%
Promoter & Promoter Group 53.9%
DIIs: Mutual Funds, AIFs and QIBs FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs Others: Retail, Bodies Corporate and others
Key Investors
31
Doctors Connect Program in Q3 FY25
Vijaya Diagnostics organised a webinar on Ovarian-Adnexal Reporting & Data system Ultrasonic (O-RADS US)
Vijaya Diagnostics organised a webinar on the role of CECT abdomen in management of pancreatic carcinoma
Vijaya Diagnostics organised a webinar on Xray scannogram of lower limb
Vijaya Diagnostics organised a webinar on PET-CT in Tirupati
32
Awards & Accolades
Icon in Integrated Diagnostic
Services by Times Health
Excellence 2024 - TS & AP
Most Preferred Workplace for
Women 2024 – 25 recognized
by Marksmen Daily
Most Trusted Brand of India
2024-25 awarded by
Marksmen Daily – 4th edition
Fastest Growing Leaders 2023-
24 awarded at Asian business &
Social Forum 2024, Dubai
Fastest Growing Brands 2023-
24 awarded at Asian business &
Social Forum 2024, Dubai
Best Healthcare Brands’ 2024
Best Brand awarded at ET Edge
recognized by ET Edge
Awards 2023
Excellence In Comprehensive
Diagnostic Care awarded by
ABP Ananda Swasthya Samman
Best Healthcare Brands’
awarded by Economic Times -
2023
Most Trusted Brand of India
awarded by Marksmen Daily –
3rd edition
One of the Most Preferred
Workplace 2022 awarded by
team Marksmen
Best Healthcare Brands’
awarded by Economic Times -
2022
Best Healthcare Brands’
awarded by Economic Times -
2021
Company of the Year 2021 -
Healthcare presented by
TV9 Network and SAP
Leading Diagnostic Chain of
the Year 2021 presented by
Diagnostic Leadership Summit
33
Disclaimer
Note 2: Disclaimer "With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value (“WDV") method to Straight Line Method (“SLM"), based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets.”
Due to the aforesaid change, the Profit after tax (PAT) for the year Financial year ended March 31, 2023 and Financial year ended March 31, 2024 was higher by Rs 67.7 Mn and Rs 290.8 Mn respectively.
Note 3: Acquisition (PH Diagnostic Centre Private Limited, Pune) : PH has become a whole owned subsidiary effective from 21st December 2023. Consequently, its financials have been consolidated from 21st December 2023 in the last financial year FY 2023-24. The consolidated revenue from operations for the Financial year ended March 31, 2024 includes Rs 130.6 Mn from PH.
All financial and operational figures of FY 24 and FY 25 in the subsequent slides are including PH (Consolidated from 21st Dec, 23 till 31st Mar, 2024)
34
Annexure
Strategic Expansion
State-of-the-art Infrastructure (1/3)
36
State-of-the-art Infrastructure (2/3)
37
State-of-the-art Infrastructure (3/3)
38
Advanced Equipment in Place to Deliver High Quality Services (1/2)
39
Advanced Equipment in Place to Deliver High Quality Services (2/2)
40
Robust Operational Metrics
Diagnostic Centre (Nos)
Footfalls (Mn)
Tests Performed (Mn)
145
121
2.79
2.63
3.62
3.55
3.18
11.89
9.32
10.05
7.91
7.09
73
80
95
FY20
FY21
FY22
FY23
FY 24
FY20
FY21
FY22
FY23
FY 24
FY20
FY21
FY22
FY23
FY 24
Test per Footfall (Nos)
Impact of COVID-19
2.83
2.69
2.57
3.17
3.35
Revenue per Test (INR)
Revenue per Footfall (INR)
531
496
457
461
428
1,431
1,276
1,214
1,446
1,543
FY20
FY21
FY22
FY23
FY24
FY20
FY21
FY22
FY23
FY 24
FY20
FY21
FY22
FY23
FY 24
41
Consistent Financial Performance
Revenue
CAGR:12.8%
EBIDTA
CAGR:13.6%
4,624
4,592
5,478
3,388
3,767
2,037
1,820
2,209
1,660
1,326
PAT
CAGR:17.4%
1,097
845
846
1,188
625
FY20
FY21
FY22
FY23
FY24
FY20
FY21
FY22
FY23
FY24
FY20
FY21
FY22
FY23
FY24
EBIDTA Margin (%)
120 bps
44.1% 44.1%
39.1%
39.6%
40.3%
PAT Margin (%)
320 bps
18.5%
22.4% 23.7%
21.7%
18.4%
FY20
FY21
FY22
FY23
FY24
FY20
FY21
FY22
FY23
FY24
Integrated business model with high B2C concentration (~93%) and a strong brand recall has resulted in Industry leading margins
42
(INR Mn)
Sustainable Cash Generation & Increasing Return Ratios
(INR Mn)
1,729
Cash & Cash Equivalents
2,277
2,466
2,554
1,822
CFO (1) / EBIDTA (%)
90%
83%
80%
78%
77%
FY20
FY21
FY22
FY23
FY 24
FY20
FY21
FY22
FY23
FY 24
RoCE Pre-Cash (2) (%)
43%
38%
33%
25%
23%
RoE (%)
23%
23%
23%
18%
16%
FY20
FY21
FY22
FY23
FY 24
FY20 FY21 Note: Refer Slide no. 3
FY22
FY23
FY 24
43
1. CFO = Cash flow from Operations
2. ROCE (Pre-cash): PBIT ex Other income / (Total Assets – Cash – Current Liabilities)
Consolidated Profit & Loss Account
Particulars
Revenue from operations
Cost of materials consumed
Employee benefits expense
Other expenses
EBITDA
EBITDA %
Other income
Depreciation and amortization expense
EBIT Finance costs
Profit before tax and exceptional items
Exceptional items
Profit before Tax
Tax expenses
Profit after Tax before Minority Interest
Minority Interest
Profit after Tax
PAT %
EPS – Basic (INR)
FY24
FY23
FY22
FY21
FY20
5,478
654
902
1,712
2,209
40.3%
208
570
1,847
240
1,607
21
1,587
390
1,196
8
1,188
21.7%
11.62
4,592
589
785
1,398
1,820
39.6%
142
617
1,344
209
1,135
-
1,135
283
852
5.8
846
18.4%
8.29
4,624
715
707
1,165
2,037
44.1%
128
527
1,638
165
1,474
-
1,474
367
1,107
10
1,097
23.7%
10.76
3,767
571
574
962
1,660
44.1%
118
505
1,274
152
1,121
-
1,121
270
851
6
845
22.4%
8.28
3,388
439
624
999
1,326
39.1%
154
492
988
154
834
-
834
209
625
0
625
18.5%
6.13
(INR Mn)
44
Consolidated Balance Sheet
Assets
Mar-24 Mar-23 Mar-22 Mar-21 Mar-20
Equity & Liabilities
Mar-24 Mar-23 Mar-22 Mar-21 Mar-20
NON-CURRENT ASSETS Property, plant and equipment Capital work-in-progress Goodwill Other intangible assets Right of use asset Intangible assets under development Financial assets - Investments - Other financial assets Deferred tax assets Income tax assets Other assets
CURRENT ASSETS Inventories Financial assets - Investments - Trade receivables - Cash and cash equivalents - Bank balances other than Cash and cash equivalents - Loans - Other financial assets Other current assets
7,714 3,785 83 1,192 207 2,235 5
0 113 29 2 62
5,777 2,940 271 53 22 2,223 6
0 90 83 2 85
4,436 1,966 341 53 14 1,672 1
0 75 89 2 223
3,022 1,358 82 53 6 1,260 12
0 122 61 6 61
2,959 1,398 93 53 10 1,254 4
0 55 16 9 67
2,113 52
2,757 20
2,698 43
2,388 26
1,865 28
1,091 162 222
1,390 95 242
542 98 110
276 64 67
508
922
1,813
1,876
0 31 46
0 36 51
0 51 41
0 52 27
547 80 556
626
1 5 22
EQUITY Equity share capital Instruments entirely equity in nature Other equity
6,599 102 - 6,497
5,466 102 - 5,364
4,695 102 - 4,593
3,592 45 - 3,547
2,741 45 - 2,696
NON-CURRENT LIABILITIES
2,500
2,406
1,778
1,377
1,494
Financial liabilities
- Borrowings - Lease liabilities - Other financial liabilities Provisions Other liabilities
CURRENT LIABILITIES Financial liabilities - Borrowings - Lease liabilities - Trade payables - Other financial liabilities Income tax liabilities Provisions Other liabilities
0 2,391 0 106 3
0 2,330 0 71 5
0 1,703 0 74 1
33 1,265 2 77 1
221 1,196 9 67 1
729
662
661
440
589
0 201 329 114 12 32 40
0 145 277 140 24 40 36
6 126 216 248 9 21 35
12 101 222 61 16 7 20
13 88 217 224 15 11 21
TOTAL ASSETS
9,828
8,534
7,135
5,409
4,824
TOTAL EQUITY AND LIABILITIES
9,828
8,534
7,135
5,409
4,824
45
(INR Mn)
Consolidated Cash Flow Statement
Particulars
Cash Flow from Operating Activities Profit before Tax Adjustment for Non-Operating Items Operating Profit before Working Capital Changes Changes in Working Capital Cash Generated from Operations Less: Direct Taxes paid Net Cash from Operating Activities Purchase and construction of property, plant and building (net) Acquisition of subsidiary Investments (net) Others Cash Flow from Investing Activities Cash Flow from Financing Activities Net increase/ (decrease) in Cash & Cash equivalent Cash & Cash Equivalents at the beginning of the period Cash & Cash equivalents at the end of the period
Cash and Cash Equivalents
Particulars
Investments* Cash and cash equivalents Bank balances other than Cash and cash equivalents Total
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
1,587 599 2,186 -14 2,172 -339 1,833 -880 -1,475 530 401 -1,423 -445 -36 258 222
1,135 683 1,818 90 1,908 -262 1,646 -1,248 - 734 887 -1,096 -419 131 110 242
1,474 572 2,046 -67 1,979 -399 1,580 -1,223 - -127 120 -1,231 -306 44 67 110
1,121 534 1,655 -46 1,609 -312 1,297 -312 - -1,033 47 -1,298 -488 -489 556 67
834 492 1,326 -32 1,294 -233 1,061 -375 - 11 57 -306 -295 460 96 556
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
1,092 222 508
1,822
1,390 242 922
2,554
542 110 1,813
2,465
335 67 1,876
2,277
547 556 626
1,729
46
(INR Mn)
*Current investments + investments with maturity more than 12 months (part of other non-current financial assets)
Thank You
For further information please contact:
Mr. Dhiren Gala AGM - Strategy & Investor Relations +91 90598 93206
dhiren.g@vijayadiagnostic.in ir@vijayadiagnostic.in
www.vijayadiagnostic.com
Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.